Expression of Syndecan-1 in Chronic Liver Diseases: Correlation With Hepatic Fibrosis

In Vivo. 2021 Jan-Feb;35(1):333-339. doi: 10.21873/invivo.12264.

Abstract

Background/aim: The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis.

Materials and methods: Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated.

Results: According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p<0.012) and intermediate (p<0.003) fibrosis.

Conclusion: In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis.

Keywords: Heparan sulfate proteoglycans; immunohistochemistry; liver fibrosis; syndecan-1.

MeSH terms

  • Humans
  • Immunohistochemistry
  • Liver Cirrhosis / genetics
  • Membrane Glycoproteins*
  • Syndecan-1* / genetics

Substances

  • Membrane Glycoproteins
  • SDC1 protein, human
  • Syndecan-1